pegylated interferon alpha-2a
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
biologic medication |
| gptkbp:activeIngredient |
interferon alpha-2a
|
| gptkbp:approvedBy |
gptkb:FDA
2002 |
| gptkbp:ATCCode |
L03AB11
|
| gptkbp:brand |
gptkb:Pegasys
|
| gptkbp:contraindication |
autoimmune hepatitis
decompensated liver disease |
| gptkbp:developedBy |
gptkb:Hoffmann-La_Roche
|
| gptkbp:eliminatedIn |
renal
hepatic |
| gptkbp:halfLife |
about 80 hours
|
| gptkbp:hasModification |
gptkb:plastic
|
| https://www.w3.org/2000/01/rdf-schema#label |
pegylated interferon alpha-2a
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
immunomodulation
antiviral activity |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia neutropenia flu-like symptoms |
| gptkbp:usedFor |
gptkb:chronic_hepatitis_C
chronic hepatitis B |
| gptkbp:bfsParent |
gptkb:peginterferon_alfa-2a
|
| gptkbp:bfsLayer |
8
|